RxDoctor Payments Data

Victoria Seligman, MD

Rheumatology · Denver, CONPI 1609906460

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.6% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 28.3% of the total. Reporting peaked in 2022 at $1,798 and has fallen 94.5% since, to $98 in 2024.

$3,833in general payments, 2019–2025

Across 157 payments — averaging $24.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$946
  • Novartis$420
  • AstraZeneca$200
  • UCB, Inc.$192
  • Janssen Scientific Affairs, LLC$174
  • plus $817 from 12 others

What the payments were for

  • Consulting fees$632%
  • Food & beverage$3,74198%
  • Education$291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,833 in reported general payments places this provider in the 65th percentile of 108 rheumatology providers in Colorado.

See all rheumatology providers in Colorado

Medicare billing

Part B allowed, 2024
$8,480
Medicare patients
48
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab12$93,584
Alendronate Sodium18$547
Gabapentin16$321
Tramadol Hcl17$173
Omeprazole11$164
Rosuvastatin Calcium16$152
Levothyroxine Sodium19$88
Trazodone Hcl17$80
Lisinopril13$79
Prednisone11$56

Paid to pharmacies, not to this prescriber.

Other rheumatology in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →